Benedetto Vitiello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6268547/publications.pdf

Version: 2024-02-01

143 12,450 50
papers citations h-inde

50 108
h-index g-index

143 143 all docs citations

143 times ranked 9917 citing authors

#	Article	IF	CITATIONS
1	Trends in admissions to a child and adolescent neuropsychiatric inpatient unit in the 2007–2017 decade: how contemporary neuropsychiatry is changing in Northwestern Italy. European Child and Adolescent Psychiatry, 2022, 31, 1527-1537.	4.7	5
2	Obsessive–compulsive symptoms in young women affected with anorexia nervosa, and their relationship with personality, psychopathology, and attachment style. Eating and Weight Disorders, 2022, 27, 1193-1207.	2.5	5
3	Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British Journal of Clinical Pharmacology, 2022, 88, 4965-4984.	2.4	21
4	Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review. Brain Sciences, 2022, 12, 176.	2.3	4
5	Acute Tolerability of Methylphenidate in Treatment-NaÃ ⁻ ve Children with ADHD: An Analysis of Naturalistically Collected Data from Clinical Practice. Paediatric Drugs, 2022, 24, 147-154.	3.1	6
6	Sexual Differences in Internet Gaming Disorder (IGD): From Psychological Features to Neuroanatomical Networks. Journal of Clinical Medicine, 2022, 11, 1018.	2.4	7
7	Impact of war and forced displacement on children's mental healthâ€"multilevel, needs-oriented, and trauma-informed approaches. European Child and Adolescent Psychiatry, 2022, 31, 845-853.	4.7	67
8	Association between EEG Paroxysmal Abnormalities and Levels of Plasma Amino Acids and Urinary Organic Acids in Children with Autism Spectrum Disorder. Children, 2022, 9, 540.	1.5	4
9	Emotional Dysregulation and Adaptive Functioning in Preschoolers With Autism Spectrum Disorder or Other Neurodevelopmental Disorders. Frontiers in Psychiatry, 2022, 13, 846146.	2.6	7
10	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. European Neuropsychopharmacology, 2022, 59, 45-55.	0.7	7
11	Epilepsy in a cohort of children with Noonan syndrome and related disorders. European Journal of Pediatrics, 2022, 181, 2919-2926.	2.7	4
12	Enhanced Expression of Human Endogenous Retroviruses, TRIM28 and SETDB1 in Autism Spectrum Disorder. International Journal of Molecular Sciences, 2022, 23, 5964.	4.1	6
13	Paths to postsecondary education enrollment among adolescents with and without childhood attentionâ€deficit/hyperactivity disorder (ADHD): A longitudinal analysis of symptom and academic trajectories. Child Development, 2022, 93, .	3.0	1
14	Cognitive, neuropsychological and emotional-behavioural functioning in a sample of children with myotonic dystrophy type 1. European Journal of Paediatric Neurology, 2022, 39, 59-64.	1.6	3
15	Improving Recognition of Treatable Rare Neuromuscular Disorders in Primary Care: A Pilot Feasibility Study. Children, 2022, 9, 1063.	1.5	2
16	Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 816-817.	0.5	4
17	The song of Anorexia Nervosa: a specific evoked potential response to musical stimuli in affected participants. Eating and Weight Disorders, 2021, 26, 807-816.	2.5	6
18	Affectionless control: A parenting style associated with obesity and binge eating disorder in adulthood. European Eating Disorders Review, 2021, 29, 178-192.	4.1	12

#	Article	IF	CITATIONS
19	A psychological support group for parents in the care of families with gender diverse children and adolescents. Clinical Child Psychology and Psychiatry, 2021, 26, 64-78.	1.6	10
20	Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder. Journal of Child and Family Studies, 2021, 30, 784-792.	1.3	4
21	What Do We Know about the Long-Term Course of Early Onset Bipolar Disorder? A Review of the Current Evidence. Brain Sciences, 2021, 11, 341.	2.3	12
22	Psychological Impact of the COVID-19 Pandemic on Adults and Their Children in Italy. Frontiers in Psychiatry, 2021, 12, 572997.	2.6	86
23	Impact of the COVID-19 Pandemic on Child and Adolescent Psychiatric Emergencies. Journal of Clinical Psychiatry, 2021, 82, .	2.2	36
24	Emotional imagination of negative situations: Functional neuroimaging in anorexia and bulimia. PLoS ONE, 2021, 16, e0231684.	2.5	2
25	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, , .	0.5	6
26	Editorial: On the Safety of Long-term Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder in Early Childhood. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, , .	0.5	0
27	Psychopathological profile in children with Prader-Willi syndrome as compared with autism spectrum disorder. Minerva Pediatrics, 2021, , .	0.4	0
28	Psychopathology and Adaptive Functioning in Children, Adolescents, and Young Adults with Noonan Syndrome. Journal of Developmental and Behavioral Pediatrics, 2021, Publish Ahead of Print, .	1.1	4
29	The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110326.	4.8	47
30	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
31	Development and application of a diagnostic and severity scale to grade post-operative pediatric cerebellar mutism syndrome. European Journal of Pediatrics, 2021, , .	2.7	2
32	Assessing Cognitive Function in Neuromuscular Diseases: A Pilot Study in a Sample of Children and Adolescents. Journal of Clinical Medicine, 2021, 10, 4777.	2.4	6
33	Where have the children with epilepsy gone? An observational study of seizure-related accesses to emergency department at the time of COVID-19. Seizure: the Journal of the British Epilepsy Association, 2020, 83, 38-40.	2.0	20
34	Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol. Contemporary Clinical Trials, 2020, 99, 106184.	1.8	6
35	Challenges and burden of the Coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: a narrative review to highlight clinical and research needs in the acute phase and the long return to normality. Child and Adolescent Psychiatry and Mental Health, 2020, 14, 20.	2.5	1,149
36	Child and adolescent mental health service provision and research during the Covid-19 pandemic: challenges, opportunities, and a call for submissions. Child and Adolescent Psychiatry and Mental Health, 2020, 14, 19.	2.5	54

#	Article	IF	Citations
37	Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents. CNS Spectrums, 2020, 26, 1-9.	1.2	1
38	Does population density moderate suicide risk? An Italian population study over the last 30Âyears. European Psychiatry, 2020, 63, e70.	0.2	17
39	Youth depression: are two treatments better than one?. Lancet Psychiatry, the, 2019, 6, 714-715.	7.4	4
40	Maladaptive Aggression: With a Focus on Impulsive Aggression in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 576-591.	1.3	45
41	Clinical and personality characteristics of adolescents with anorexia nervosa with or without non-suicidal self-injurious behavior. Comprehensive Psychiatry, 2019, 94, 152115.	3.1	19
42	New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges. Expert Review of Clinical Pharmacology, 2019, 12, 757-770.	3.1	12
43	Clinical Correlates of Parenting Stress in Children with Autism Spectrum Disorder and Serious Behavioral Problems. Journal of Child and Family Studies, 2019, 28, 2069-2077.	1.3	26
44	Challenges in assessing the therapeutic benefit of lithium in children and adolescents with bipolar disorder. Bipolar Disorders, 2019, 21, 556-557.	1.9	0
45	An exploration of concomitant psychiatric disorders in children with autism spectrum disorder. Comprehensive Psychiatry, 2019, 88, 57-64.	3.1	72
46	Cigarette Smoking Progression Among Young Adults Diagnosed With ADHD in Childhood: A 16-year Longitudinal Study of Children With and Without ADHD. Nicotine and Tobacco Research, 2019, 21, 638-647.	2.6	21
47	Substance use through adolescence into early adulthood after childhoodâ€diagnosed ADHD: findings from the MTA longitudinal study. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2018, 59, 692-702.	5.2	81
48	Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evidence-Based Mental Health, 2018, 21, e10-e10.	4.5	15
49	Anticonvulsants for Psychiatric Disorders in Children and Adolescents: A Systematic Review of Their Efficacy. Frontiers in Psychiatry, 2018, 9, 270.	2.6	17
50	Acute Hemichorea Can Be the Only Clinical Manifestation of Post-Varicella Vasculopathy: Two Pediatric Clinical Cases. Frontiers in Neurology, 2018, 9, 164.	2.4	4
51	Psychotic Symptoms in Attention-Deficit/Hyperactivity Disorder: An Analysis of the MTA Database. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 336-343.	0.5	17
52	New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. CNS Drugs, 2017, 31, 149-160.	5.9	25
53	Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 125-131.	1.3	17
54	Young adult outcomes in the followâ€up of the multimodal treatment study of attentionâ€deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2017, 58, 663-678.	5.2	207

#	Article	IF	Citations
55	The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors. Critical Reviews in Food Science and Nutrition, 2016, 56, 2560-2578.	10.3	78
56	Pharmacological treatment of children and adolescents with depression. Expert Opinion on Pharmacotherapy, 2016, 17, 2273-2279.	1.8	33
57	No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 900-908.	1.3	7
58	New journal structure of child and adolescent psychiatry and mental health. Child and Adolescent Psychiatry and Mental Health, 2016, 10, 35.	2.5	0
59	Sensitivity of the modified Children's Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. Autism, 2016, 20, 145-152.	4.1	7
60	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 415-423.	0.5	61
61	Pharmacotherapy of the Preschool ADHD Treatment StudyÂ(PATS) Children Growing Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 550-556.	0.5	30
62	Child psychiatry services in Asia: evolving state of affairs?. Child and Adolescent Psychiatry and Mental Health, 2015, 9, 12.	2.5	2
63	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. European Neuropsychopharmacology, 2015, 25, 1513-1531.	0.7	56
64	Improving outcome of paediatric depression with cognitive–behavioural therapy (CBT) after initial improvement on antidepressant medication. Evidence-Based Mental Health, 2015, 18, 64-64.	4.5	0
65	Practical Clinical Trials in Psychopharmacology. Journal of Clinical Psychopharmacology, 2015, 35, 178-183.	1.4	5
66	Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 482-493.	1.3	61
67	Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 999-1007.e4.	0.5	33
68	Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1008-1019.	0.5	22
69	Development of a Physiologically Based Model to Describe the Pharmacokinetics of Methylphenidate in Juvenile and Adult Humans and Nonhuman Primates. PLoS ONE, 2014, 9, e106101.	2.5	21
70	Prevalence of psychiatric symptoms in children and adolescents one year after the 2009 L'Aquila earthquake. BMC Psychiatry, 2014, 14, 270.	2.6	26
71	Children's Yale–Brown Obsessive Compulsive Scale in Autism Spectrum Disorder: Component Structure and Correlates of Symptom Checklist. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 97-107.e1.	0.5	55
72	Examination of Aggression and Self-injury in Children with Autism Spectrum Disorders and Serious Behavioral Problems. Child and Adolescent Psychiatric Clinics of North America, 2014, 23, 57-72.	1.9	47

#	Article	IF	Citations
73	Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders. Journal of Developmental and Physical Disabilities, 2013, 25, 355-371.	1.6	16
74	Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials. Journal of Autism and Developmental Disorders, 2013, 43, 739-746.	2.7	45
75	How Effective are the Current Treatments for Children Diagnosed with Manic/Mixed Bipolar Disorder?. CNS Drugs, 2013, 27, 331-333.	5.9	1
76	In Reply. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 206-207.	0.5	0
77	The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 264-278.e2.	0.5	162
78	Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 2013, 43, 2341-2352.	2.7	149
79	Adolescent Substance Use in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a Function of Childhood ADHD, Random Assignment to Childhood Treatments, and Subsequent Medication. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 250-263.	0.5	217
80	The Development of Targeted Neurobiological Therapies in Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 775-779.	0.5	2
81	Medication Use in US Youth With Mental Disorders. JAMA Pediatrics, 2013, 167, 141.	6.2	75
82	A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Archives of General Psychiatry, 2012, 69, 515.	12.3	201
83	Blood Pressure and Heart Rate Over 10 Years in the Multimodal Treatment Study of Children With ADHD. American Journal of Psychiatry, 2012, 169, 167-177.	7.2	79
84	Stimulant Medication Use in Children: A 12-Year Perspective. American Journal of Psychiatry, 2012, 169, 160-166.	7.2	210
85	Effects of Risperidone and Parent Training on Adaptive Functioning in Children With Pervasive Developmental Disorders and Serious Behavioral Problems. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 136-146.	0.5	89
86	Out of the Black Box: Treatment of Resistant Depression in Adolescents and the Antidepressant Controversy. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 5-10.	1.3	11
87	Treatment Moderators and Predictors of Outcome in the Treatment of Early Age Mania (TEAM) Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 867-878.	0.5	47
88	Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 496-505.	0.5	37
89	Economic Evaluation of Strategies to Reduce Sudden Cardiac Death in Young Athletes. Pediatrics, 2012, 130, e380-e389.	2.1	46
90	The genetic toxicity of methylphenidate: a review of the current literature. Journal of Applied Toxicology, 2012, 32, 756-764.	2.8	6

#	Article	IF	CITATIONS
91	Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. Journal of Affective Disorders, 2012, 138, 86-95.	4.1	45
92	Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder. CNS Drugs, 2011, 25, 503-509.	5.9	23
93	Impact of Physical and Sexual Abuse on Treatment Response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 293-301.	0.5	76
94	Suicide Attempts and Nonsuicidal Self-Injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 772-781.	0.5	460
95	Reporting clinical trials of psychosocial interventions in child and adolescent psychiatry and mental health. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 4.	2.5	11
96	Antidepressant Exposure as a Predictor of Clinical Outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) Study. Journal of Clinical Psychopharmacology, 2011, 31, 92-97.	1.4	52
97	Children's hospitalizations with a mood disorder diagnosis in general hospitals in the united states 2000-2006. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 27.	2.5	15
98	Pubertal delay in male nonhuman primates (<i>Macaca mulatta</i>) treated with methylphenidate. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16301-16306.	7.1	34
99	Incremental Cost-effectiveness of Combined Therapy vs Medication Only for Youth With Selective Serotonin Reuptake Inhibitor–Resistant Depression. Archives of General Psychiatry, 2011, 68, 253.	12.3	43
100	Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 555-564.	1.3	24
101	Long-Term Outcome of Adolescent Depression Initially Resistant to Selective Serotonin Reuptake Inhibitor Treatment. Journal of Clinical Psychiatry, 2011, 72, 388-396.	2.2	102
102	Safeguarding Childrens Rights in Psychopharmacological Research: Ethical and Legal Issues. Current Pharmaceutical Design, 2010, 16, 2398-2406.	1.9	30
103	Obsessive–compulsive traits in children and adolescents with Asperger syndrome. European Child and Adolescent Psychiatry, 2010, 19, 17-24.	4.7	85
104	The Importance of the Discourse on the Method. Child and Adolescent Psychiatry and Mental Health, 2010, 4, 2.	2.5	1
105	Modeled Economic Evaluation of Alternative Strategies to Reduce Sudden Cardiac Death Among Children Treated for Attention Deficit/Hyperactivity Disorder. Circulation, 2010, 121, 1329-1337.	1.6	36
106	Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 83-93.	1.3	53
107	Possible Influence of Variant of the P-Glycoprotein Gene (MDR1/ABCB1) on Clinical Response to Guanfacine in Children with Pervasive Developmental Disorders and Hyperactivity. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 1-5.	1.3	26
108	Association of FKBP5 Polymorphisms With Suicidal Events in the Treatment of Resistant Depression in Adolescents (TORDIA) Study. American Journal of Psychiatry, 2010, 167, 190-197.	7.2	128

#	Article	IF	CITATIONS
109	Parent-Reported Homework Problems in the MTA Study: Evidence for Sustained Improvement with Behavioral Treatment. Journal of Clinical Child and Adolescent Psychology, 2010, 39, 220-233.	3.4	56
110	Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 Outcomes. American Journal of Psychiatry, 2010, 167, 782-791.	7.2	159
111	Dr. Aman et al. reply. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 407-408.	0.5	1
112	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 583-594.	0.5	86
113	Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 52-60.	0.5	23
114	Pharmacotherapy for Children and Adolescents with Anxiety Disorders. Psychiatric Annals, 2010, 40, 185-191.	0.1	10
115	Treatment Response in Depressed Adolescents With and Without Co-Morbid Attention-Deficit/Hyperactivity Disorder in the Treatment for Adolescents with Depression Study. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 519-527.	1.3	33
116	The Treatment for Adolescents With Depression Study (TADS): Outcomes Over 1 Year of Naturalistic Follow-Up. American Journal of Psychiatry, 2009, 166, 1141-1149.	7.2	114
117	Stimulant Treatment of ADHD and Risk of Sudden Death in Children. American Journal of Psychiatry, 2009, 166, 955-957.	7.2	15
118	Clinical Messages From the Treatment for Adolescents With Depression Study (TADS). American Journal of Psychiatry, 2009, 166, 1118-1123.	7.2	104
119	Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders, 2009, 39, 720-729.	2.7	35
120	Cognitive-Behavioral Therapy for Suicide Prevention (CBT-SP): Treatment Model, Feasibility, and Acceptability. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1005-1013.	0.5	318
121	Service Use and Costs of Care for Depressed Adolescents: Who Uses and Who Pays?. Journal of Clinical Child and Adolescent Psychology, 2009, 38, 826-836.	3.4	11
122	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology, 2009, 19, 629-635.	0.7	184
123	Substance Use and the Treatment of Resistant Depression in Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1182-1192.	0.5	54
124	The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 484-500.	0.5	968
125	Relative Cost-Effectiveness of Treatments for Adolescent Depression: 36-Week Results From the TADS Randomized Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 711-720.	0.5	62
126	Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1143-1154.	0.5	279

#	Article	IF	CITATIONS
127	The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of Suicidal Events in an Open Treatment Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 987-996.	0.5	219
128	Depressive Symptoms and Clinical Status During the Treatment of Adolescent Suicide Attempters (TASA) Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 997-1004.	0.5	68
129	Sources of site differences in the efficacy of a multisite clinical trial: The treatment of SSRI-resistant depression in adolescents Journal of Consulting and Clinical Psychology, 2009, 77, 439-450.	2.0	23
130	Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression. JAMA - Journal of the American Medical Association, 2008, 299, 901.	7.4	571
131	Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 593-603.	1.3	55
132	Texas Children's Medication Algorithm Project: Update From Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 667-686.	0.5	146
133	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 969-978.	0.5	64
134	Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1284-1293.	0.5	409
135	Safety and Tolerability of Methylphenidate in Preschool Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1294-1303.	0.5	211
136	Selecting an Antidepressant for the Treatment of Pediatric Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 371-373.	0.5	11
137	Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1314-1322.	0.5	116
138	National Estimates of Antidepressant Medication Use Among U.S. Children, 1997-2002. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 271-279.	0.5	70
139	Stimulant-Related Reductions of Growth Rates in the PATS. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1304-1313.	0.5	201
140	Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS). Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1275-1283.	0.5	125
141	Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression. JAMA - Journal of the American Medical Association, 2004, 292, 807.	7.4	1,432
142	Impairment and Deportment Responses to Different Methylphenidate Doses in Children With ADHD: The MTA Titration Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 180-187.	0.5	252
143	Cognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans. Neuropsychopharmacology, 1997, 16, 15-24.	5.4	86